12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oral salmon calcitonin: Phase II data

The double-blind, U.S. Phase II TAR01-201 trial in 129 postmenopausal women with low bone mass at an increased risk of fracture showed that once-daily 200 mg oral Ostora met the primary endpoint of superiority to placebo in percent change from baseline in lumbar spine BMD at 1 year (p=0.026). Specifically, Ostora significantly improved lumbar spine BMD by 1.03% at 1 year compared to baseline (p<0.001), while placebo led to a 0.12% reduction in lumbar spine BMD from baseline to 1 year. Additionally, Ostora led to a significant placebo-adjusted reduction in levels of fasting CTX-I, a biomarker of bone resorption activity, of 20.2%...

Read the full 487 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >